<?xml version='1.0' encoding='utf-8'?>
<document id="22712629"><sentence text="A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers."><entity charOffset="78-94" id="DDI-PubMed.22712629.s1.e0" text="dextromethorphan" /><entity charOffset="95-104" id="DDI-PubMed.22712629.s1.e1" text="quinidine" /><entity charOffset="109-118" id="DDI-PubMed.22712629.s1.e2" text="memantine" /><pair ddi="false" e1="DDI-PubMed.22712629.s1.e0" e2="DDI-PubMed.22712629.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22712629.s1.e0" e2="DDI-PubMed.22712629.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s1.e0" e2="DDI-PubMed.22712629.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22712629.s1.e1" e2="DDI-PubMed.22712629.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s1.e1" e2="DDI-PubMed.22712629.s1.e2" /></sentence><sentence text="Dextromethorphan/quinidine (DMQ) is the first agent indicated for the treatment of pseudobulbar affect"><entity charOffset="0-16" id="DDI-PubMed.22712629.s2.e0" text="Dextromethorphan" /><entity charOffset="17-26" id="DDI-PubMed.22712629.s2.e1" text="quinidine" /><entity charOffset="28-31" id="DDI-PubMed.22712629.s2.e2" text="DMQ" /><pair ddi="false" e1="DDI-PubMed.22712629.s2.e0" e2="DDI-PubMed.22712629.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22712629.s2.e0" e2="DDI-PubMed.22712629.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s2.e0" e2="DDI-PubMed.22712629.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22712629.s2.e1" e2="DDI-PubMed.22712629.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s2.e1" e2="DDI-PubMed.22712629.s2.e2" /></sentence><sentence text=" Dextromethorphan, the active ingredient, is a low-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist"><entity charOffset="1-17" id="DDI-PubMed.22712629.s3.e0" text="Dextromethorphan" /><entity charOffset="75-95" id="DDI-PubMed.22712629.s3.e1" text="N-methyl-D-aspartate" /><entity charOffset="97-101" id="DDI-PubMed.22712629.s3.e2" text="NMDA" /><pair ddi="false" e1="DDI-PubMed.22712629.s3.e0" e2="DDI-PubMed.22712629.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22712629.s3.e0" e2="DDI-PubMed.22712629.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s3.e0" e2="DDI-PubMed.22712629.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22712629.s3.e1" e2="DDI-PubMed.22712629.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s3.e1" e2="DDI-PubMed.22712629.s3.e2" /></sentence><sentence text=" This study evaluated the potential for a drug-drug interaction (DDI) of DMQ with memantine, which is also an NMDA receptor antagonist"><entity charOffset="82-91" id="DDI-PubMed.22712629.s4.e0" text="memantine" /><entity charOffset="73-81" id="DDI-PubMed.22712629.s4.e1" text="DMQ" /><entity charOffset="110-118" id="DDI-PubMed.22712629.s4.e2" text="NMDA" /><pair ddi="false" e1="DDI-PubMed.22712629.s4.e1" e2="DDI-PubMed.22712629.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s4.e1" e2="DDI-PubMed.22712629.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22712629.s4.e1" e2="DDI-PubMed.22712629.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22712629.s4.e0" e2="DDI-PubMed.22712629.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22712629.s4.e0" e2="DDI-PubMed.22712629.s4.e2" /></sentence><sentence text="" /><sentence text="This open-label, randomized, parallel-group study enrolled healthy adults who were randomized into one of two treatment groups" /><sentence text=" Group 1 subjects were administered memantine at a starting dose of 5 mg once daily, which was titrated over a 3-week period to a dose of 10 mg twice daily (every 12 hours) and continued for another 11 days to attain steady state; DMQ 30 mg (dextromethorphan 30 mg/quinidine 30 mg) every 12 hours was then added for a further 8 days"><entity charOffset="36-45" id="DDI-PubMed.22712629.s7.e0" text="memantine" /><entity charOffset="242-258" id="DDI-PubMed.22712629.s7.e1" text="dextromethorphan" /><entity charOffset="265-274" id="DDI-PubMed.22712629.s7.e2" text="quinidine" /><entity charOffset="231-239" id="DDI-PubMed.22712629.s7.e3" text="DMQ" /><pair ddi="false" e1="DDI-PubMed.22712629.s7.e0" e2="DDI-PubMed.22712629.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22712629.s7.e0" e2="DDI-PubMed.22712629.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22712629.s7.e0" e2="DDI-PubMed.22712629.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s7.e0" e2="DDI-PubMed.22712629.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22712629.s7.e3" e2="DDI-PubMed.22712629.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22712629.s7.e3" e2="DDI-PubMed.22712629.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s7.e3" e2="DDI-PubMed.22712629.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22712629.s7.e1" e2="DDI-PubMed.22712629.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s7.e1" e2="DDI-PubMed.22712629.s7.e2" /></sentence><sentence text=" Group 2 subjects received DMQ 30 mg every 12 hours for 8 days to attain steady state; memantine was then added, titrated on the same schedule as in group 1, and continued at 10 mg every 12 hours for an additional 11 days"><entity charOffset="87-96" id="DDI-PubMed.22712629.s8.e0" text="memantine" /><entity charOffset="27-35" id="DDI-PubMed.22712629.s8.e1" text="DMQ" /><pair ddi="false" e1="DDI-PubMed.22712629.s8.e1" e2="DDI-PubMed.22712629.s8.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s8.e1" e2="DDI-PubMed.22712629.s8.e0" /></sentence><sentence text=" Pharmacokinetic blood sampling was performed to assess the primary endpoints of the 90% confidence intervals (CIs) for the geometric mean ratios of the areas under the plasma concentration-time curves (AUCs) for memantine, dextromethorphan, dextrorphan - the dextromethorphan metabolite - and quinidine during concomitant therapy versus monotherapy"><entity charOffset="213-222" id="DDI-PubMed.22712629.s9.e0" text="memantine" /><entity charOffset="224-240" id="DDI-PubMed.22712629.s9.e1" text="dextromethorphan" /><entity charOffset="242-253" id="DDI-PubMed.22712629.s9.e2" text="dextrorphan" /><entity charOffset="260-276" id="DDI-PubMed.22712629.s9.e3" text="dextromethorphan" /><entity charOffset="294-303" id="DDI-PubMed.22712629.s9.e4" text="quinidine" /><pair ddi="false" e1="DDI-PubMed.22712629.s9.e0" e2="DDI-PubMed.22712629.s9.e0" /><pair ddi="false" e1="DDI-PubMed.22712629.s9.e0" e2="DDI-PubMed.22712629.s9.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s9.e0" e2="DDI-PubMed.22712629.s9.e2" /><pair ddi="false" e1="DDI-PubMed.22712629.s9.e0" e2="DDI-PubMed.22712629.s9.e3" /><pair ddi="false" e1="DDI-PubMed.22712629.s9.e0" e2="DDI-PubMed.22712629.s9.e4" /><pair ddi="false" e1="DDI-PubMed.22712629.s9.e1" e2="DDI-PubMed.22712629.s9.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s9.e1" e2="DDI-PubMed.22712629.s9.e2" /><pair ddi="false" e1="DDI-PubMed.22712629.s9.e1" e2="DDI-PubMed.22712629.s9.e3" /><pair ddi="false" e1="DDI-PubMed.22712629.s9.e1" e2="DDI-PubMed.22712629.s9.e4" /><pair ddi="false" e1="DDI-PubMed.22712629.s9.e2" e2="DDI-PubMed.22712629.s9.e2" /><pair ddi="false" e1="DDI-PubMed.22712629.s9.e2" e2="DDI-PubMed.22712629.s9.e3" /><pair ddi="false" e1="DDI-PubMed.22712629.s9.e2" e2="DDI-PubMed.22712629.s9.e4" /><pair ddi="false" e1="DDI-PubMed.22712629.s9.e3" e2="DDI-PubMed.22712629.s9.e3" /><pair ddi="false" e1="DDI-PubMed.22712629.s9.e3" e2="DDI-PubMed.22712629.s9.e4" /></sentence><sentence text=" Safety/tolerability and pharmacodynamic variables were also assessed" /><sentence text="" /><sentence text="A total of 52 subjects were randomized" /><sentence text=" In both group 1 (n = 23) and group 2 (n = 29), the 90% CIs for the ratios of the AUCs during concomitant therapy versus monotherapy were within the predefined range to indicate similarity (0" /><sentence text="8-1" /><sentence text="25) for memantine, dextromethorphan and dextrorphan, indicating no pharmacokinetic DDI"><entity charOffset="8-17" id="DDI-PubMed.22712629.s15.e0" text="memantine" /><entity charOffset="19-35" id="DDI-PubMed.22712629.s15.e1" text="dextromethorphan" /><entity charOffset="40-51" id="DDI-PubMed.22712629.s15.e2" text="dextrorphan" /><pair ddi="false" e1="DDI-PubMed.22712629.s15.e0" e2="DDI-PubMed.22712629.s15.e0" /><pair ddi="false" e1="DDI-PubMed.22712629.s15.e0" e2="DDI-PubMed.22712629.s15.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s15.e0" e2="DDI-PubMed.22712629.s15.e2" /><pair ddi="false" e1="DDI-PubMed.22712629.s15.e1" e2="DDI-PubMed.22712629.s15.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s15.e1" e2="DDI-PubMed.22712629.s15.e2" /></sentence><sentence text=" The 90% CI for the AUC ratio for quinidine was slightly above the predefined range; however, the mean AUC increased by only 25%"><entity charOffset="9-11" id="DDI-PubMed.22712629.s16.e0" text="CI" /><entity charOffset="34-43" id="DDI-PubMed.22712629.s16.e1" text="quinidine" /><pair ddi="false" e1="DDI-PubMed.22712629.s16.e0" e2="DDI-PubMed.22712629.s16.e0" /><pair ddi="false" e1="DDI-PubMed.22712629.s16.e0" e2="DDI-PubMed.22712629.s16.e1" /></sentence><sentence text=" In both groups, incidence of adverse events was similar, and pharmacodynamic variables were either similar or slightly improved with DMQ added to memantine and memantine added to DMQ, compared to monotherapy with either agent"><entity charOffset="147-156" id="DDI-PubMed.22712629.s17.e0" text="memantine" /><entity charOffset="161-170" id="DDI-PubMed.22712629.s17.e1" text="memantine" /><entity charOffset="134-142" id="DDI-PubMed.22712629.s17.e2" text="DMQ" /><entity charOffset="180-188" id="DDI-PubMed.22712629.s17.e3" text="DMQ" /><pair ddi="false" e1="DDI-PubMed.22712629.s17.e2" e2="DDI-PubMed.22712629.s17.e2" /><pair ddi="false" e1="DDI-PubMed.22712629.s17.e2" e2="DDI-PubMed.22712629.s17.e0" /><pair ddi="false" e1="DDI-PubMed.22712629.s17.e2" e2="DDI-PubMed.22712629.s17.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s17.e2" e2="DDI-PubMed.22712629.s17.e3" /><pair ddi="false" e1="DDI-PubMed.22712629.s17.e0" e2="DDI-PubMed.22712629.s17.e0" /><pair ddi="false" e1="DDI-PubMed.22712629.s17.e0" e2="DDI-PubMed.22712629.s17.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s17.e0" e2="DDI-PubMed.22712629.s17.e3" /><pair ddi="false" e1="DDI-PubMed.22712629.s17.e1" e2="DDI-PubMed.22712629.s17.e1" /><pair ddi="false" e1="DDI-PubMed.22712629.s17.e1" e2="DDI-PubMed.22712629.s17.e3" /></sentence><sentence text="" /><sentence text="Minimal pharmacokinetic and pharmacodynamic interactions were observed between memantine and DMQ, suggesting they can be coadministered without dose adjustment"><entity charOffset="79-88" id="DDI-PubMed.22712629.s19.e0" text="memantine" /><entity charOffset="93-96" id="DDI-PubMed.22712629.s19.e1" text="DMQ" /><pair ddi="false" e1="DDI-PubMed.22712629.s19.e0" e2="DDI-PubMed.22712629.s19.e0" /><pair ddi="false" e1="DDI-PubMed.22712629.s19.e0" e2="DDI-PubMed.22712629.s19.e1" /></sentence><sentence text="" /></document>